A retrospective study of efficacy, survival and safety of secukinumab treatment in patients with spondyloarthritis and psoriatic arthritis
Latest Information Update: 23 Jun 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism